Curis, Inc.
Curis, Inc.
Your view on CRIS
Overview
What the company does, where it operates, and who runs it.
About Curis, Inc.
- Industry
- Biotechnology
- Sector
- Healthcare
- CEO
- James E. Dentzer
- Headquarters
- Building C, Lexington, MA, US
- Industry
- Biotechnology
- Sector
- Healthcare
- CEO
- James E. Dentzer
- Headquarters
- Building C, Lexington, MA, US
Curis, Inc., a biotechnology company, engages in the discovery and development of drug candidates for the treatment of human cancers in the United States.
Its clinical stage drug candidates include Emavusertib, an oral small molecule drug candidate, which is in a Phase 1/2 clinical trial for the treatment of non-hodgkin lymphomas, and acute myeloid leukemia and myelodysplastic syndromes; and CI-8993, a monoclonal antibody designed to antagonize the V-domain Ig suppressor of T cell activation.
The company's pipeline also includes Fimepinostat, an oral dual inhibitor of HDAC and PI3K enzymes for the treatment of patients with MYC-altered diffuse large B-cell lymphoma; CA-170, an oral small molecule drug candidate for treating patients with advanced solid tumors and lymphomas; and CA-327, a pre-investigational new drug stage oncology drug candidate.
It has collaboration agreement with F. Hoffmann-La Roche Ltd. and Genentech Inc. for the development and commercialization of Erivedge, an orally-administered small molecule hedgehog signaling pathway inhibitor for the treatment of advanced basal cell carcinoma; and with Aurigene Discovery Technologies Limited for the discovery, development, and commercialization of small molecule compounds in the areas of immuno-oncology and precision oncology. Curis, Inc. was incorporated in 2000 and is headquartered in Lexington, Massachusetts.
Stock Data
Price chart, volume, and trading data.
Fair Value
What FRC thinks it is worth vs. the current price.
Fair value for Curis, Inc. from FRC's valuation model, read against the market price. CRIS last traded at $0.59; the estimate is read against that market price. The model runs on every stock on the platform and shows the estimate per share and the date it was calculated. A free account covers 3 company valuations a month; a paid subscription is unlimited.
Financial Ratios
Profitability, returns, valuation, and leverage ratios.
Valuation, profitability, liquidity and leverage ratios for Curis, Inc.. Starting points for Curis, Inc.: EPS -$9.90, beta 3.25 — an Biotechnology name. P/E, P/B, EV/EBITDA, margins, return on equity, current ratio and debt coverage, each shown against the company's own history.
Dividend Analysis
Yield, payout ratio, and dividend coverage metrics.
Dividend history, yield and payout sustainability for Curis, Inc.. Curis, Inc. does not currently pay a regular dividend, so this section tracks capacity rather than history. Per-share payments, yield over time, payout ratio and growth streak, with coverage measured against free cash flow.
Earnings Analysis
EPS history, beat rate, and upcoming earnings reports.
Reported vs. expected earnings history for Curis, Inc.. Trailing twelve-month EPS for Curis, Inc. stands at -$9.90. EPS surprises by quarter, revenue against estimates, and the upcoming reporting date.
Analyst Estimates
Analysts' price targets, ratings, and revenue and EPS estimates.
Analyst Ratings
- Strong Buy0
- Buy16
- Hold2
- Sell0
- Strong Sell0
Earnings Estimate
| EPS | Current QtrSep 2026 | Next QtrDec 2026 | Current YearFY Dec 2026 | Next YearFY Dec 2027 |
|---|---|---|---|---|
| Avg. estimate | -$2.01 | -$1.63 | -$32.48 | -$5.03 |
| Low estimate | -$2.01 | -$1.63 | -$68.08 | -$10.53 |
| High estimate | -$2.01 | -$1.63 | -$14.45 | -$2.23 |
| No. of analysts | 1 | 1 | 2 | 2 |
| Year-ago EPS | -$9.80 | $24.60 | -$11.60 | — |
| Growth | +79.5% | -106.6% | -180.0% | — |
Revenue Estimate
| Revenue | Current QtrSep 2026 | Next QtrDec 2026 | Current YearFY Dec 2026 | Next YearFY Dec 2027 |
|---|---|---|---|---|
| Avg. estimate | $1.00M | $333333.00 | $1.75M | $12.33M |
| Low estimate | $1.00M | $333331.00 | $1.00M | $7.07M |
| High estimate | $1.00M | $333334.00 | $3.23M | $22.73M |
| No. of analysts | 2 | 3 | 2 | 3 |
| Year-ago revenue | $3.18M | $1.14M | $9.44M | — |
| Growth | -68.5% | -70.7% | -81.5% | — |
Source: Wall Street analysts' published price targets, ratings and estimates, compiled by Financial Modeling Prep; as of Nov 12, 2026. Not FRC research or a recommendation.
Financial Statements
Income statement, balance sheet, and cash flow statements.
Income statement, balance sheet and cash flow history for Curis, Inc.. Curis, Inc. has reported as a listed company since 2000. Annual and quarterly filings with period-over-period comparison, so you can trace how revenue, margins and cash generation have moved.
Comparables
List of peer companies in the same industry.
Curis, Inc. valued side by side against its closest peers. Curis, Inc. is measured against Biotechnology peers within the Healthcare sector. Peer-relative multiples and operating metrics, so the valuation is read in the context of its own sector rather than in isolation.
Institutional Ownership
Which funds and firms own the stock.
Which institutions hold Curis, Inc., and how their positions are changing. At a $1.2M market value, institutional positions materially move Curis, Inc.'s register. Top holders, position sizes, and quarter-over-quarter accumulation or distribution from regulatory filings.
Insider Trading
Recent buying and selling by company executives.
Buying and selling by Curis, Inc. executives and directors. Shares of Curis, Inc. have traded between $1.02 and $4.70 over the past 52 weeks — context for the timing of the transactions below. Insider transactions as disclosed to regulators, with role, size and date — the clearest read on how the people running the company are positioned.
News
Latest headlines and market coverage.
Latest headlines and company announcements for Curis, Inc.. Coverage tracks Curis, Inc. within Biotechnology (Healthcare). Press releases and market coverage, newest first.
Comments
Comments and replies from FRC members about this company.
No comments yet
Be the first to ask a question or say what you make of Curis, Inc.